AIMM Therapeutics' Pre-Fusion RSV Antibodies Facilitate Improved Approach to Vaccine Development

Published: Nov 04, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AMSTERDAM--(BUSINESS WIRE)--AIMM Therapeutics B.V., a leading developer of a new generation of therapeutic antibodies, announced today that researchers have used the Company’s unique family of antibodies that neutralize respiratory syncytial virus (RSV) to engineer an improved vaccine against RSV. In a paper published in Science titled ‘Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus’1, a team of scientists from the Vaccine Research Center (VRC) at the U.S. National Institute of Allergy and Infectious Diseases describe how structural biology insight into how AIMM’s highly potent RSV antibodies work enabled them to engineer a vaccine immunogen able to trigger a response 40 times higher than needed to neutralize RSV infection.

Help employers find you! Check out all the jobs and post your resume.

Back to news